Colchicine

> 如果你痛风发作，最害怕的是什么？大概率不是这一次的疼痛，而是下一次——不知道什么时候，关节又会突然红肿，疼到鞋都穿不上。这种“不知道下一次在哪”的恐惧，才是全中国约3.2%的痛风患者共同的噩梦。几十年来，国内痛风治疗一直困在“痛了就吃、不痛就停”的循环里，直到2025年，一款名为**伏欣奇拜单抗（商品名金蓓欣）**的新药获批上市，带来了一个颠覆性的方案：**打一针，能管半年。** ## 从“关水龙头”到“关总闸”，精准打击炎症源头 要理解这个新药为什么厉害，得先搞清楚痛风到底是怎么发生的。现在主流的说法是，痛风是因为体内尿酸太高，形成结晶沉积在关节，导致了剧烈炎症。你可以把痛风发作想象成一个水龙头坏了，水（尿酸）不停地流，但真正让你疼的，是地上那摊水（炎症）引发的滑倒和混乱。 传统药物，不管是非甾体抗炎药、秋水仙碱还是激素，都像在**疯狂地擦地**。它们能暂时缓解疼痛，但无法阻止炎症本身，而且擦地的方法还各有各的副作用：有的伤胃、有的伤肾、有的影响心血管。更麻烦的是，你永远不知道水龙头什么时候又会滴水，所以下次发作随时可能到来。 而伏欣奇拜单抗，做的是**直接去关掉那个总闸**。它精准地靶向一种叫IL-1β（白介素-1β）的炎症核心因子，可以理解为直接掐断了引发痛风炎症的“总开关”。 因为它不是广谱地抑制所有免疫反应，所以避免了传统药物“杀敌一千，自损八百”的副作用，对肝肾、胃肠道的负担显著降低。 ## 一针管半年，把不可预测的疼痛变成可管理的慢性病 真正的革命发生在给药方式上。伏欣奇拜单抗的半衰期长达25.5到30.8天，这意味着单次皮下注射后，它能在体内持续工作很久。关键Ⅲ期临床试验给出了一个极具冲击力的数据：**单次给药后，24周内痛风复发风险降低了近90%**。 在长达48周的随访里，患者平均只打了1.6次针。这相当于从每天都要想着吃药，变成了半年去一次医院。 这带来的不仅仅是方便，更是治疗逻辑的根本改变。 过去，痛风患者，尤其是那些需要启动降尿酸治疗的，会经历一个非常痛苦的“溶晶痛”阶段。简单说，就是血尿酸在下降时，关节里的尿酸盐结晶开始溶解，会反而诱发一次次的痛风发作。 很多人因为受不了这个反复的疼痛，干脆放弃了降尿酸治疗，导致病情越来越重，痛风石、肾损伤接踵而至。 伏欣奇拜单抗完美地解决了这个死结。它用长达半年的抗炎保护，为降尿酸治疗创造了一个安稳的“窗口期”。患者可以在不痛的情况下，安心地服用降尿酸药，把血尿酸稳定在目标值，直到结晶溶解，走向真正的长期稳定。 正如金赛药业的创始人金磊博士所说，这让痛风治疗从“**控制症状**”走向了“**控制病因**”。 ## 从痛风出发，一个“药王”潜质的产品集群初现 作为国内首个痛风治疗领域的1类创新生物制剂，金蓓欣的价值远不止于痛风。它背后的IL-1β靶点，还是一个可以探索更多疾病领域的宝藏。 金赛药业正围绕这个靶点，布局下一个重磅产品集群，包括子宫内膜异位症、间质性肺病、非感染性葡萄膜炎、糖尿病肾病等，这些适应症的全球潜在市场规模合计超过250亿美元。 可以说，金蓓欣不仅是继百亿级生长激素后，长春高新和金赛药业找到的“下一个生长激素”，更是企业从单一聚焦生长激素及辅助生殖领域转向覆盖成人慢病、免疫、代谢等多元领域的关键战略支点。 这款药的成功，也让它接连入选了工信部首批“**生物制造标志性产品**”名单和“**2025年中国医药生物技术十大进展**”，从国家产业政策和行业技术双维度，印证了其原始创新的价值。 它证明了中国药企不仅能做仿制药，也能在“不拥挤、高潜力”的靶点上，做出全球领先的、真正解决临床痛点的创新药。 对于广大痛风患者来说，最大的认知转变或许是：痛风不再是一种只能靠“忍”和“扛”的疼痛性疾病，它正成为一种可以长期管理、甚至能打断发作循环的慢性病。而这一切的改变，都始于一个全新的治疗逻辑——**以长效抗炎，护航降尿酸达标，最终实现全病程管理**。

PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced the signing of a binding term sheet with iHolding Group LLP ("iHolding"), a private investment group headquartered in Almaty, Republic of Kazakhstan. The term sheet contemplates that iHolding will purchase $100,000,000 of newly issued shares of Scilex common stock. The purchase price for such shares is expected to be $15.00 per share, which would represent approximately 6,666,667 shares. The proposed investment would be used to support Scilex's continued strategic growth, including expansion of its healthcare and medical technology initiatives, product development and commercialization, acquisitions and strategic partnerships, working capital and operational growth, intellectual property expansion, and other general corporate purposes. The proposed investment remains subject to completion of customary due diligence, the parties’ negotiation and execution of definitive agreements, board approvals, and other customary closing conditions, including receipt of the approval of Scilex’s stockholders and any required regulatory approvals. Joint Statement by Alain Khoueiry, Chairman, and Byron Byrd, Chief Executive Officer, iHolding Group LLP: “Our proposed investment in Scilex Holding Company has the potential to become a significant strategic milestone, demonstrating the growing international capability of Kazakhstan-linked investment capital to participate in innovative healthcare and biotechnology opportunities. Scilex has established a diversified portfolio that combines commercial pain management products with an expanding pipeline of innovative therapies addressing important unmet medical needs. This combination of marketed products, product development, intellectual property, and continued innovation represents the type of healthcare platform that complements iHolding’s long-term investment philosophy. Importantly, this initiative aligns directly with our vision of helping establish Kazakhstan as a leading regional hub for pharmaceutical manufacturing, research and development, biotechnology innovation, regulatory excellence, and international healthcare distribution. Every strategic collaboration of this quality enhances the expertise, supply chain relationships, regulatory knowledge, and global industry connections necessary to build a sustainable life sciences ecosystem capable of serving both Central Asia and international markets. Our objective extends well beyond a single investment. We are committed to creating strategic partnerships that accelerate innovation, attract world-class healthcare organizations, expand international collaboration, and contribute meaningfully to Kazakhstan’s long-term economic, scientific, and healthcare development. Through partnerships such as this, we are laying the foundations for a globally connected pharmaceutical and biotechnology sector that can benefit future generations.” iHolding Group LLP is a private investment vehicle based in the Medeu District of Almaty, Kazakhstan, with a focus on healthcare, technology, and cross-border strategic investments. The proposed investment represents one of the largest Kazakhstan-origin healthcare investments into a U.S.-listed biopharmaceutical company in recent years, underscores growing international interest in Scilex's differentiated commercial platform and pipeline. This press release shall not constitute an offer to sell or a solicitation of an offer to buy Scilex securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. For more information on Scilex Holding Company, refer to For more information on Semnur Pharmaceuticals, Inc., refer to For more information on ZTlido® including Full Prescribing Information, refer to . For more information on ELYXYB®, including Full Prescribing Information, refer to . For more information on Gloperba®, including Full Prescribing Information, refer to . info@scilexholding.com About Scilex Holding Company Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur Pharmaceuticals, Inc. (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. Scilex is headquartered in Palo Alto, California. About Semnur Pharmaceuticals, Inc. Semnur Pharmaceuticals, Inc. (“Semnur”) is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. Semnur is headquartered in Palo Alto, California About iHolding Group LLP iHolding Group LLP is a private investment group headquartered in Almaty, Republic of Kazakhstan, focused on strategic capital deployment across healthcare, technology, and commercial sectors. iHolding seeks investments in companies with strong intellectual property platforms and meaningful global growth potential. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, the expected execution of definitive agreements, the closing of the proposed investment and whether the proposed investment can support Scilex’s continued strategic growth. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business. These risks and uncertainties include, but are not limited to, delays or inability to complete due diligence, execute definitive agreements, or obtain any necessary approvals for the proposed investment, including board, stockholder and regulatory approvals; general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements. Contacts: Investors and Media Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Office: (650) 516-4310 Email: investorrelations@scilexholding.com Website: SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company. ELYXYB® is a registered trademark owned by Scilex Holding Company. Scilex Bio™ is a trademark owned by Scilex Holding Company. All other trademarks are the property of their respective owners. © 2026 Scilex Holding Company All Rights Reserved.